One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in the rat

Pharmacology Biochemistry and Behavior

Volumn 72, Issue 4, 2002, Pages 973-978

  Cruz Morales, S E ^a   Santos, N R ^b   Brandao M L ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Elevated plus maze; Ethological analysis; Midazolam; One trial tolerance

Indexed keywords

MIDAZOLAM; ANXIOLYTIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG TOLERANCE; ETHNOPHARMACOLOGY; FEAR; IMMOBILIZATION; MALE; MAZE TEST; NONHUMAN; PHOBIA; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; ANIMAL; BODY POSTURE; DRUG EFFECT; EXPLORATORY BEHAVIOR; GROOMING; MOTOR ACTIVITY; WISTAR RAT;

ANIMAL; ANTI-ANXIETY AGENTS, BENZODIAZEPINE; BEHAVIOR, ANIMAL; EXPLORATORY BEHAVIOR; FEAR; GROOMING; MALE; MIDAZOLAM; MOTOR ACTIVITY; POSTURE; RATS; RATS, WISTAR; SUPPORT, NON-U.S. GOV'T; ANIMALS; ANTI-ANXIETY AGENTS;

ANIMALIA;

EID: 0035991314     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00813-4     Document Type: Article

References (30)

1. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze
2. Behavioral and pharmacological validation of the elevated plus-maze constructed with transparent walls
3. Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety
4. Risk assessment and animal models of anxiety
5. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain
6. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro-6028) in the murine elevated plus-maze
7. Ethopharmacological analysis of rat behavior on the plus-maze
8. The influence of open arm ledges and maze experience in the elevated plus-maze
9. One trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze
10. Behavioural detection of anxiolytic action
11. "One trial tolerance" to the anxiolytic actions of benzodiazepine in the elevated plus-maze, or the development of a phobic state?
12. Trial 2 in the elevated plus maze: A different form of fear?
13. 5-HT and mechanisms of defence
14. Fundamentals of the septo-hippocampal system
15. Some critical determinants of the behaviour of rats in the elevated plus-maze
16. 5-HT drugs in animal models of anxiety
17. Multiple serotonin mechanisms in animal models of anxiety: Environmental, emotional and cognitive factors
18. Responses of Swiss-Webster mice to repeated plus-maze as experience: Further evidence for qualitative shift in emotional state
19. The use of a plus-maze to measure anxiety in the mouse
20. The relationship between fear induced by novel stimulation and exploratory behaviour
21. Aversive and anti-aversive effects of morphine in the periaqueductal gray of rats submitted to the elevated plus-maze test
22. Effects of microinfections of μ and κ receptors agonists in the dorsal periaqueductal gray of rats submitted to the plus maze
23. The pharmacology of human anxiety
24. Validation of open:closed arm entries in the elevated plus-maze as a measure of anxiety in the rat
25. The phenomenon of 'one-trial tolerance' to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze is abolished by the introduction of a motivational conflict situation
26. The elevated plus-maze: Pharmacology, methodology and ethology
27. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety
28. Influence of prior maze experience on behaviour and responses to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice
29. Anxiogenic stimuli in the elevated plus-maze
30. Are glutamatergic pathways involved in the pathophysiology of anxiety?